Heim038290 • KOSDAQ
add
Macrogen Inc
Við síðustu lokun
16.150,00 ₩
Dagbil
16.210,00 ₩ - 16.650,00 ₩
Árabil
14.920,00 ₩ - 26.700,00 ₩
Markaðsvirði
177,01 ma. KRW
Meðalmagn
62,86 þ.
V/H-hlutf.
-
A/V-hlutfall
1,82%
Aðalkauphöll
KOSDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 33,00 ma. | 2,20% |
Rekstrarkostnaður | 13,80 ma. | 4,68% |
Nettótekjur | -3,18 ma. | -60,92% |
Hagnaðarhlutfall | -9,64 | -57,52% |
Hagnaður á hvern hlut | — | — |
EBITDA | 2,21 ma. | 47,21% |
Virkt skatthlutfall | 1,20% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 24,60 ma. | 8,61% |
Heildareignir | 274,19 ma. | 3,79% |
Heildarskuldir | 124,82 ma. | 40,99% |
Eigið fé alls | 149,37 ma. | — |
Útistandandi hlutabréf | 9,97 m. | — |
Eiginfjárgengi | 1,09 | — |
Arðsemi eigna | -0,54% | — |
Ávöxtun eigin fjár | -0,70% | — |
Peningaflæði
Breyting á handbæru fé
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -3,18 ma. | -60,92% |
Handbært fé frá rekstri | -2,08 ma. | 50,99% |
Reiðufé frá fjárfestingum | -9,57 ma. | -22,48% |
Reiðufé frá fjármögnun | 6,73 ma. | 594,06% |
Breyting á handbæru fé | -4,51 ma. | 58,99% |
Frjálst peningaflæði | -10,07 ma. | 35,34% |
Um
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Framkvæmdastjóri
Stofnsett
5. jún. 1997
Vefsvæði
Starfsfólk
519
